ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years
Di Feng
Matched on ORCID iD 0000-0002-1444-3510; OpenAlex author ID A5101451608. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- Demethylzeylasteral suppresses the expression of MESP1 by reducing H3K18la level to inhibit the malignant behaviors of pancreatic cancer. Co-author DOI 10.1038/s41420-025-02603-9↗
- Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. First author DOI 10.1016/j.phymed.2021.153537↗
- UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed, paraffin‑embedded and optimal cutting t… Co-author DOI 10.3892/ijo.2019.4898↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Haocheng Zhang · 1 shared paper, 2025 · strength 0.27
- Xiaolei Ma · 1 shared paper, 2025 · strength 0.27
- Guofen Qiao · 1 shared paper, 2025 · strength 0.27
- Mancang Gu · 2 shared papers, 2019–2021 · strength 0.21
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537↗
- Paper UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed,… DOI 10.3892/ijo.2019.4898↗
- Yifan Qian · 2 shared papers, 2019–2021 · strength 0.21
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537↗
- Paper UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed,… DOI 10.3892/ijo.2019.4898↗
- Liping Chen · 1 shared paper, 2021 · strength 0.12
- Yafang Qian · 1 shared paper, 2021 · strength 0.12
- Li Liu · 1 shared paper, 2019 · strength 0.09
- Yan Xia Shi · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.